Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Director Sells 4,010 Shares

Key Points

• Director Elizabeth Kwo sold 4,010 shares of Kestra Medical Technologies at an average price of $24.26, totaling $97,282.60. The sale was made to cover tax withholding tied to vested equity awards, reducing her direct ownership by 22.12% to 14,116 shares.
• KMTS shares fell 2.2% to $25.51, while the company reported quarterly revenue of $30.97 million and an adjusted loss of $0.75 per share, missing the consensus estimate of a $0.61 loss.
• Analyst sentiment is mixed, with four Buy ratings, two Holds, and one Sell; the overall consensus is Hold, with an average price target of $28.38.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) Director Elizabeth Kwo sold 4,010 shares of the firm's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $24.26, for a total transaction of $97,282.60. Following the transaction, the director directly owned 14,116 shares of the company's stock, valued at approximately $342,454.16. This represents a 22.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 2.2%

Shares of Kestra Medical Technologies stock traded down $0.58 during trading on Wednesday, reaching $25.51. The company had a trading volume of 222,727 shares, compared to its average volume of 344,534. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69. Kestra Medical Technologies, Ltd. has a fifty-two week low of $17.34 and a fifty-two week high of $30.00. The firm's fifty day moving average is $25.11 and its 200-day moving average is $22.72. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -9.55 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last posted its quarterly earnings results on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%.The firm had revenue of $30.97 million during the quarter. On average, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Oppenheimer initiated coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a "market perform" rating on the stock. BTIG Research reiterated a "buy" rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Royal Bank Of Canada set a $30.00 target price on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Piper Sandler reaffirmed an "overweight" rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Finally, Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $28.38.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KMTS. Brown Advisory Inc. increased its position in Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company's stock worth $44,775,000 after buying an additional 428,996 shares during the period. Eventide Asset Management LLC boosted its holdings in shares of Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company's stock valued at $33,671,000 after acquiring an additional 65,288 shares during the period. Next Century Growth Investors LLC grew its position in shares of Kestra Medical Technologies by 154.5% during the fourth quarter. Next Century Growth Investors LLC now owns 465,845 shares of the company's stock worth $12,354,000 after acquiring an additional 282,832 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in shares of Kestra Medical Technologies during the fourth quarter worth about $9,282,000. Finally, Sei Investments Co. increased its holdings in shares of Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company's stock worth $4,726,000 after acquiring an additional 43,753 shares during the period.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company's primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient's heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.